Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 187 matching trials from the live ClinicalTrials.gov search.
Conditions
Parkinson's Disease
Interventions
Levodopa (delivered intravenously)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Amblyopia
Interventions
levodopa/carbidopa, patching
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
8 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Not applicable Interventional Results available

Erythromycin in Parkinson's Disease

NCT02005029
Conditions
Parkinson's Disease, Levodopa
Interventions
Erythromycin, placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Parkinson's Disease
Interventions
No intervention.
Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Rochester, New York
Conditions
Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 13 more
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence

NCT01468012
Conditions
Cocaine Dependence
Interventions
levodopa carbidopa and entacapone (LCE), Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years and older
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Parkinson Disease, Autonomic Nervous System Diseases, Pure Autonomic Failure
Interventions
6-[18F]Fluorodopamine, 6-[18F]Fluorodopa, 13N-Ammonia
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 4 Interventional Results available

Effect of L-dopa In Subacute Back Pain Population

NCT01951105
Conditions
Sub-acute Back Pain
Interventions
Naproxen, Carbidopa/Levodopa, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Parkinson Disease
Interventions
CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Congenital Hyperinsulinism
Interventions
18F-Fluoro Dopa Imaging
Drug
Lead sponsor
Miguel Pampaloni
Other
Eligibility
0 Days to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Parkinson's Disease
Interventions
Istradefylline
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Parkinson's Disease
Interventions
VY-AADC01
Biological
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
San Francisco, California • Pittsburgh, Pennsylvania
Terminated Phase 2 Interventional Results available

Vision Response to Dopamine Replacement

NCT01663935
Conditions
Albinism, Oculocutaneous Albinism
Interventions
Levodopa/carbidopa
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
3 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Parkinson Disease
Interventions
AP-472, Placebo
Drug · Other
Lead sponsor
Appello Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more
Conditions
Parkinson's Disease
Interventions
Apomorphine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Parkinson Disease
Interventions
ropinirole/L-dopa, placebo/L-dopa
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Fountain Valley, California • Pasadena, California • Reseda, California + 6 more
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Sun City, Arizona • Loma Linda, California • Orange, California + 9 more
Conditions
Parkinson Disease
Interventions
Lenrispodun, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
40 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
35
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 31 more
Completed Phase 3 Interventional Results available

Levodopa for the Treatment of Residual Amblyopia

NCT01190813
Conditions
Amblyopia
Interventions
Levodopa/Carbidopa, Placebo, Patching
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 12 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Parkinson Disease
Interventions
Levodopameter
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
San Diego, California
Conditions
Parkinson Disease, Parkinsonian Syndrome
Interventions
levodopa, Mirapex (pramipexole), [123I]ß-CIT and SPECT imaging
Drug · Procedure
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
Oxnard, California • Englewood, Colorado • New Haven, Connecticut + 9 more
Conditions
Parkinson's Disease, Dyskinesia
Interventions
Sarizotan HCl
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
30 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
17
States / cities
Fountain Valley, California • Sunnyvale, California • Miami, Florida + 14 more
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate, rasagiline mesylate 1.0 mg
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
7
States / cities
Fresno, California • Atlanta, Georgia • Chicago, Illinois + 4 more